Abstract
To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antitubercular Agents / therapeutic use*
-
Female
-
Humans
-
Interferon-gamma / blood*
-
Isoniazid / therapeutic use*
-
Lymphocyte Activation
-
Male
-
Middle Aged
-
Mycobacterium tuberculosis / immunology*
-
Reagent Kits, Diagnostic*
-
Skin Tests
-
Treatment Outcome
-
Tuberculin / immunology
-
Tuberculosis / drug therapy*
-
Tuberculosis / immunology
-
Tuberculosis / microbiology
Substances
-
Antitubercular Agents
-
Reagent Kits, Diagnostic
-
Tuberculin
-
Interferon-gamma
-
Isoniazid